UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000014110 |
|---|---|
| Receipt number | R000016425 |
| Scientific Title | Effect of anti-vascular endothelial growth factor (VEGF) drugs in chronic central serous chorioretinopathy (CSC) |
| Date of disclosure of the study information | 2014/06/01 |
| Last modified on | 2018/12/01 12:58:37 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
Effect of anti-vascular endothelial growth factor (VEGF) drugs in chronic central serous chorioretinopathy (CSC)
Acronym
Effect of anti-VEGF drugs in chronic CSC
Scientific Title
Effect of anti-vascular endothelial growth factor (VEGF) drugs in chronic central serous chorioretinopathy (CSC)
Scientific Title:Acronym
Effect of anti-VEGF drugs in chronic CSC
Region
| Japan |
Condition
Condition
chronic central serous chorioretinopathy
Classification by specialty
| Ophthalmology |
Classification by malignancy
Others
Genomic information
NO
Objectives
Narrative objectives1
To investigate the effect of anti-VEGF drugs on visual acuity and retinal morphology in chronic CSC
Basic objectives2
Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase
Assessment
Primary outcomes
1) Ratio of patients with improved/maintained best-corrected visual acuity (BCVA) at month 1,3,6,12
2) Ratio of patients with improved central retinal thickness (CRT) at month 1,3,6,12
Key secondary outcomes
Change of BCVA, CRT etc.
Base
Study type
Interventional
Study design
Basic design
Single arm
Randomization
Non-randomized
Randomization unit
Blinding
Open -no one is blinded
Control
Uncontrolled
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
1
Purpose of intervention
Treatment
Type of intervention
| Medicine |
Interventions/Control_1
ranibizumab
pegaputanib
aflibercept
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| Not applicable |
Age-upper limit
| Not applicable |
Gender
Male and Female
Key inclusion criteria
1) Willingness to provide written informed consent
2) Chronic CSC on fluorescein angiography (FA), indocyanine green angiography (IA), optical coherence tomography (OCT)
Key exclusion criteria
none
Target sample size
10
Research contact person
Name of lead principal investigator
| 1st name | |
| Middle name | |
| Last name | Tsuyoshi Otsuji |
Organization
Kansai medical university takii hospital
Division name
Department of Ophthalmology
Zip code
Address
10-15 Fumizono-cho Moriguchi, Osaka
TEL
06-6992-1001
otsuji@takii.kmu.ac.jp
Public contact
Name of contact person
| 1st name | |
| Middle name | |
| Last name | Tsuyoshi Otsuji |
Organization
Kansai medical university takii hospital
Division name
Department of Ophthalmology
Zip code
Address
10-15 Fumizono-cho Moriguchi, Osaka
TEL
06-6992-1001
Homepage URL
otsuji@takii.kmu.ac.jp
Sponsor or person
Institute
Kansai medical university takii hospital
Institute
Department
Personal name
Funding Source
Organization
none
Organization
Division
Category of Funding Organization
Self funding
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Address
Tel
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
Other administrative information
Date of disclosure of the study information
| 2014 | Year | 06 | Month | 01 | Day |
Related information
URL releasing protocol
Publication of results
Partially published
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
No longer recruiting
Date of protocol fixation
| 2014 | Year | 05 | Month | 27 | Day |
Date of IRB
Anticipated trial start date
| 2014 | Year | 06 | Month | 02 | Day |
Last follow-up date
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
Management information
Registered date
| 2014 | Year | 05 | Month | 29 | Day |
Last modified on
| 2018 | Year | 12 | Month | 01 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000016425
